Compare ODD & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ODD | CERT |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.4M | 860.9M |
| IPO Year | 2022 | 2020 |
| Metric | ODD | CERT |
|---|---|---|
| Price | $12.39 | $5.24 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $41.00 | $11.67 |
| AVG Volume (30 Days) | 1.3M | ★ 3.2M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | N/A | $4.18 |
| Revenue Next Year | $22.92 | $5.39 |
| P/E Ratio | $16.73 | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $10.80 | $4.45 |
| 52 Week High | $79.18 | $13.88 |
| Indicator | ODD | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 35.09 | 44.91 |
| Support Level | $10.80 | $5.19 |
| Resistance Level | $16.04 | $6.47 |
| Average True Range (ATR) | 0.87 | 0.35 |
| MACD | -0.13 | -0.03 |
| Stochastic Oscillator | 15.87 | 39.65 |
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage. Geographically, the company generates majority revenue from United states followed by other countries and Israel.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.